Table 3.
Statistical analysis using repeated measures 2-way analysis of variance or 3-way analysis of variance of remifentanil during acquisition of opioid intravenous self-administration, where data are presented in Figure 3.
| Figure 2 | F (DFn, DFd) | P | ||
|---|---|---|---|---|
| Remifentanil IVSA | ||||
| Figure 3B | Reinforcers | Time | F (3, 81) = 2.581 | P = 0.0592 |
| Pain | F (1, 27) = 6.568 | P = 0.0163* | ||
| Time × pain | F (3, 81) = 0.6613 | P = 0.5782 | ||
| Figure 3C | Nose pokes | Time | F (3, 216) = 3.738 | P = 0.0120* |
| Pain | F (1, 216) = 5.271 | P = 0.0226* | ||
| Nose poke | F (1, 216) = 30.16 | P < 0.0001**** | ||
| Time × poke | F (3, 216) = 0.4089 | P = 0.7468 | ||
| Time × pain | F (3, 216) = 0.1054 | P = 0.9569 | ||
| Poke × pain | F (1, 216) = 10.03 | P = 0.0018** | ||
| Time × poke × pain | F (3, 216) = 0.1837 | P = 0.9074 | ||
| Figure 3D | Discrimination index | Time | F (3, 78) = 0.2823 | P = 0.8381 |
| Pain | F (1, 26) = 5.687 | P = 0.0247* | ||
| Time × pain | F (3, 78) = 0.1187 | P = 0.9489 | ||
| Figure 3G Day 1 |
Cumulative reinforcers | Time × pain | F (120, 3240) = 2.796 | P < 0.0001**** |
| Time | F (1.819, 49.10) = 51.26 | P < 0.0001 | ||
| Pain | F (1, 27) = 3.071 | P = 0.0910 | ||
| AUC | t = 1.753, df = 27 | P = 0.0910 | ||
| Figure 3G Day 2 |
Cumulative reinforcers | Time × pain | F (120, 3120) = 3.883 | P < 0.0001**** |
| Time | F (1.244, 32.35) = 51.42 | P < 0.0001**** | ||
| Pain | F (1, 26) = 5.814 | P = 0.0233* | ||
| AUC | t = 2.411, df = 26 | P = 0.0233* | ||
| Figure 3G Day 3 |
Cumulative reinforcers | Time × pain | F (120, 3120) = 6.429 | P < 0.0001**** |
| Time | F (1.413, 36.74) = 46.72 | P < 0.0001**** | ||
| Pain | F (1, 26) = 10.49 | P = 0.0033** | ||
| AUC | t = 3.239, df = 26 | P = 0.0033** | ||
| Figure 3G Day 4 |
Cumulative reinforcers | Time × pain | F (120, 3120) = 2.247 | P < 0.0001**** |
| Time | F (1.250, 32.50) = 50.43 | P < 0.0001**** | ||
| Pain | F (1, 26) = 3.472 | P = 0.0737 | ||
| AUC | t = 1.863, df = 26 | P = 0.0737 | ||
| Figure 3G Day 5 |
Cumulative reinforcers | Time × pain | F (120, 2880) = 6.219 | P < 0.0001**** |
| Time | F (1.444, 34.67) = 60.29 | P < 0.0001**** | ||
| Pain | F (1, 24) = 8.333 | P = 0.0081** | ||
| AUC | t = 2.934, df = 23 | P = 0.0075** | ||
| Figure 3H | Cumulative reinforcers by day and sex | Male day 1 | t = 9.343, df = 8 | P < 0.0001**** |
| Male day 2 | t = 5.239, df = 8 | P = 0.0008*** | ||
| Male day 3 | t = 5.360, df = 8 | P = 0.0007*** | ||
| Male day 4 | t = 3.827, df = 8 | P = 0.0050** | ||
| Male day 5 | t = 8.418, df = 7 | P < 0.0001**** | ||
| Female day 1 | t = 0.3854, df = 5 | P = 0.7158 | ||
| Female day 2 | t = 2.676, df = 5 | P = 0.0440* | ||
| Female day 3 | t = 12.27, df = 5 | P < 0.0001**** | ||
| Female day 4 | t = 1.355, df = 5 | P = 0.2336 | ||
| Female day 5 | t = 3.625, df = 5 | P = 0.0151* |
A 1-sample t test and Wilcoxon test were used for the cumulative reinforcers being different than theoretical value of zero. P values are provided for each of the factors (time, pain, and if there was an interaction) for active and inactive nose pokes, and number of reinforcers earned. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.
AUC, area under the curve; IVSA, intravenous self-administration.